Cargando…
Biology and grading of pleomorphic xanthoastrocytoma—what have we learned about it?
Pleomorphic xanthoastrocytoma (PXA) is a rare astrocytoma predominantly affecting children and young adults. We performed comprehensive genomic characterization on a cohort of 67 patients with histologically defined PXA (n = 53, 79%) or anaplastic PXA (A‐PXA, n = 14, 21%), including copy number anal...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018001/ https://www.ncbi.nlm.nih.gov/pubmed/32619305 http://dx.doi.org/10.1111/bpa.12874 |
_version_ | 1783674150831783936 |
---|---|
author | Vaubel, Rachael Zschernack, Valentina Tran, Quynh T. Jenkins, Sarah Caron, Alissa Milosevic, Dragana Smadbeck, James Vasmatzis, George Kandels, Daniela Gnekow, Astrid Kramm, Christof Jenkins, Robert Kipp, Benjamin R. Rodriguez, Fausto J. Orr, Brent A. Pietsch, Torsten Giannini, Caterina |
author_facet | Vaubel, Rachael Zschernack, Valentina Tran, Quynh T. Jenkins, Sarah Caron, Alissa Milosevic, Dragana Smadbeck, James Vasmatzis, George Kandels, Daniela Gnekow, Astrid Kramm, Christof Jenkins, Robert Kipp, Benjamin R. Rodriguez, Fausto J. Orr, Brent A. Pietsch, Torsten Giannini, Caterina |
author_sort | Vaubel, Rachael |
collection | PubMed |
description | Pleomorphic xanthoastrocytoma (PXA) is a rare astrocytoma predominantly affecting children and young adults. We performed comprehensive genomic characterization on a cohort of 67 patients with histologically defined PXA (n = 53, 79%) or anaplastic PXA (A‐PXA, n = 14, 21%), including copy number analysis (ThermoFisher Oncoscan, n = 67), methylation profiling (Illumina EPIC array, n = 43) and targeted next generation sequencing (n = 32). The most frequent alterations were CDKN2A/B deletion (n = 63; 94%) and BRAF p.V600E (n = 51, 76.1%). In 7 BRAF p.V600 wild‐type cases, alternative driver alterations were identified involving BRAF, RAF1 and NF1. Downstream phosphorylation of ERK kinase was uniformly present. Additional pathogenic alterations were rare, with TERT, ATRX and TP53 mutations identified in a small number of tumors, predominantly A‐PXA. Methylation‐based classification of 46 cases utilizing a comprehensive reference tumor allowed assignment to the PXA methylation class in 40 cases. A minority grouped with the methylation classes of ganglioglioma or pilocytic astrocytoma (n = 2), anaplastic pilocytic astrocytoma (n = 2) or control tissues (n = 2). In 9 cases, tissue was available from matched primary and recurrent tumors, including 8 with anaplastic transformation. At recurrence, two tumors acquired TERT promoter mutations and the majority demonstrated additional non‐recurrent copy number alterations. Methylation class was preserved at recurrence. For 62 patients (92.5%), clinical follow‐up data were available (median follow‐up, 5.4 years). Overall survival was significantly different between PXA and A‐PXA (5‐year OS 80.8% vs. 47.6%; P = 0.0009) but not progression‐free survival (5‐year PFS 59.9% vs. 39.8%; P = 0.05). WHO grade remained a strong predictor of overall survival when limited to 38 cases defined as PXA by methylation‐based classification. Our data confirm the importance of WHO grading in histologically and epigenetically defined PXA. Methylation‐based classification may be helpful in cases with ambiguous morphology, but is largely confirmatory in PXA with well‐defined morphology. |
format | Online Article Text |
id | pubmed-8018001 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80180012021-09-03 Biology and grading of pleomorphic xanthoastrocytoma—what have we learned about it? Vaubel, Rachael Zschernack, Valentina Tran, Quynh T. Jenkins, Sarah Caron, Alissa Milosevic, Dragana Smadbeck, James Vasmatzis, George Kandels, Daniela Gnekow, Astrid Kramm, Christof Jenkins, Robert Kipp, Benjamin R. Rodriguez, Fausto J. Orr, Brent A. Pietsch, Torsten Giannini, Caterina Brain Pathol Research Articles Pleomorphic xanthoastrocytoma (PXA) is a rare astrocytoma predominantly affecting children and young adults. We performed comprehensive genomic characterization on a cohort of 67 patients with histologically defined PXA (n = 53, 79%) or anaplastic PXA (A‐PXA, n = 14, 21%), including copy number analysis (ThermoFisher Oncoscan, n = 67), methylation profiling (Illumina EPIC array, n = 43) and targeted next generation sequencing (n = 32). The most frequent alterations were CDKN2A/B deletion (n = 63; 94%) and BRAF p.V600E (n = 51, 76.1%). In 7 BRAF p.V600 wild‐type cases, alternative driver alterations were identified involving BRAF, RAF1 and NF1. Downstream phosphorylation of ERK kinase was uniformly present. Additional pathogenic alterations were rare, with TERT, ATRX and TP53 mutations identified in a small number of tumors, predominantly A‐PXA. Methylation‐based classification of 46 cases utilizing a comprehensive reference tumor allowed assignment to the PXA methylation class in 40 cases. A minority grouped with the methylation classes of ganglioglioma or pilocytic astrocytoma (n = 2), anaplastic pilocytic astrocytoma (n = 2) or control tissues (n = 2). In 9 cases, tissue was available from matched primary and recurrent tumors, including 8 with anaplastic transformation. At recurrence, two tumors acquired TERT promoter mutations and the majority demonstrated additional non‐recurrent copy number alterations. Methylation class was preserved at recurrence. For 62 patients (92.5%), clinical follow‐up data were available (median follow‐up, 5.4 years). Overall survival was significantly different between PXA and A‐PXA (5‐year OS 80.8% vs. 47.6%; P = 0.0009) but not progression‐free survival (5‐year PFS 59.9% vs. 39.8%; P = 0.05). WHO grade remained a strong predictor of overall survival when limited to 38 cases defined as PXA by methylation‐based classification. Our data confirm the importance of WHO grading in histologically and epigenetically defined PXA. Methylation‐based classification may be helpful in cases with ambiguous morphology, but is largely confirmatory in PXA with well‐defined morphology. John Wiley and Sons Inc. 2020-08-04 /pmc/articles/PMC8018001/ /pubmed/32619305 http://dx.doi.org/10.1111/bpa.12874 Text en © 2020 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Articles Vaubel, Rachael Zschernack, Valentina Tran, Quynh T. Jenkins, Sarah Caron, Alissa Milosevic, Dragana Smadbeck, James Vasmatzis, George Kandels, Daniela Gnekow, Astrid Kramm, Christof Jenkins, Robert Kipp, Benjamin R. Rodriguez, Fausto J. Orr, Brent A. Pietsch, Torsten Giannini, Caterina Biology and grading of pleomorphic xanthoastrocytoma—what have we learned about it? |
title | Biology and grading of pleomorphic xanthoastrocytoma—what have we learned about it? |
title_full | Biology and grading of pleomorphic xanthoastrocytoma—what have we learned about it? |
title_fullStr | Biology and grading of pleomorphic xanthoastrocytoma—what have we learned about it? |
title_full_unstemmed | Biology and grading of pleomorphic xanthoastrocytoma—what have we learned about it? |
title_short | Biology and grading of pleomorphic xanthoastrocytoma—what have we learned about it? |
title_sort | biology and grading of pleomorphic xanthoastrocytoma—what have we learned about it? |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018001/ https://www.ncbi.nlm.nih.gov/pubmed/32619305 http://dx.doi.org/10.1111/bpa.12874 |
work_keys_str_mv | AT vaubelrachael biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit AT zschernackvalentina biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit AT tranquynht biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit AT jenkinssarah biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit AT caronalissa biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit AT milosevicdragana biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit AT smadbeckjames biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit AT vasmatzisgeorge biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit AT kandelsdaniela biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit AT gnekowastrid biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit AT krammchristof biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit AT jenkinsrobert biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit AT kippbenjaminr biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit AT rodriguezfaustoj biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit AT orrbrenta biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit AT pietschtorsten biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit AT gianninicaterina biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit |